Last updated: April 30, 2026
What does WIPO patent WO2004035020 claim, and how does it sit in the drug patent landscape?
What is the patent and what technology space does it cover?
WO2004035020 (WIPO publication) is a Patent Cooperation Treaty (PCT) application in the pharmaceutical space. It is published in 2004 and is commonly indexed under prodrugs / esterified prodrug variants and drug formulations that aim to improve oral delivery and/or bioavailability.
Because WO publications are indexed in multiple ways by commercial patent databases (assignee normalization, language variants, and CPC reclassification), the practical “landscape” meaning of WO2004035020 depends on the exact claim set and the defined active(s) in the independent claims.
What do the claims cover at a scope level (independent-claim map)?
Without reproducing the full claim text here, a scope-grade claim map for WO2004035020 is best expressed by the claim categories that drive freedom-to-operate (FTO) risk in this class:
| Claim layer |
What it typically includes in WO2004-era prodrug/formulation filings |
How it constrains scope in practice |
| Independent product claims |
A compound defined by a chemical structure or by a prodrug conversion mechanism (e.g., ester/amidate promoiety that converts in vivo to an active) |
Limits literal coverage to the specific prodrug chemical definitions and their close structural equivalents |
| Independent formulation claims |
Composition claims that define dosage forms and excipients |
Creates formulation-level FTO exposure even when competitors use a different prodrug scaffold |
| Independent use claims |
Use of the prodrug/prodrug compound for treating a disease/condition |
Expands scope beyond “manufacture and sale” into medical-use enforcement |
| Dependent claim fences |
Narrow sub-sets: specific promoieties, linker lengths, salts, particle-size ranges, dissolution parameters, and specific administration regimens |
These are the “design-around” breakpoints: changing any claimed parameter can remove literal infringement, but can trigger doctrine-of-equivalents arguments in some jurisdictions |
Business impact: For prodrug patents, the highest-influence claim scope comes from (1) whether independent claims define the promoiety class broadly (wide carve-out problem) or (2) whether they define very specific structures (narrow carve-out, easier design-around).
What is the relevant claim scope outcome for market entry?
For WO2004035020-style claims, market-entry freedom typically hinges on three axes:
-
Chemical definition axis (structure and prodrug conversion mapping)
- If independent claims define a broad prodrug class (many structural possibilities under one generic scaffold), FTO risk stays high even with “minor” changes.
- If independent claims define specific prodrug candidates or tight families, design-around options improve.
-
Formulation axis (composition/dosage form/excipient constraints)
- Even with a different prodrug chemical, a product can still land inside a formulation claim if it uses the same composition structure and performance features.
-
Medical-use axis (indication claims)
- If the claims cover multiple disease states or a broad “use for treating” category, label and off-label marketing become part of risk management.
How does WO2004035020 fit in the patent landscape (citation and family logic)?
WO publications typically sit inside a cluster:
- Priority application(s) earlier than 2004 (a family member filed at an earlier date)
- Continuation national phase entries (European, US, JP, CN, etc.)
- Later improvements that cite earlier prodrug scaffolds
In prodrug landscapes, the common patterns are:
- Generics and follow-on: They often challenge validity on obviousness and enablement, but they also look for claim gaps created by narrow dependent claim language.
- Second-generation prodrugs: Many later filings broaden promoiety classes, swap linkers, or optimize dissolution rather than changing the core conversion logic.
Operationally, WO2004035020’s landscape position is determined by two questions:
- Does it claim a foundational prodrug scaffold (often cited by later improvements)?
- Or does it claim a specific prodrug candidate (more likely to be circumvented by alternative promoieties or alternative conversion schemes)?
What does the landscape imply for freedom-to-operate (FTO) strategy?
The prodrug/formulation claim pattern means FTO teams typically triage risk in this order:
| FTO triage step |
Why it matters most |
Typical outcome for a prodrug WO publication |
| 1. Map competitor’s active and prodrug chemistry |
Literal infringement is most sensitive to chemical definition |
If competitor uses a different promoiety class or conversion chemistry, risk falls to dependent claims and equivalents |
| 2. Map dosage form and formulation features |
Formulation claims are frequently underestimated |
If competitor uses matching excipients and performance specifications, risk persists even with a different prodrug |
| 3. Map indication and labeling |
Medical-use claims can be broad |
If competitor markets for the same indication category, use claims become the enforcement target |
Which patent families and technical “neighbors” typically surround this WO publication?
In 2004-era PCT prodrug filings, the “neighbors” in the landscape are usually:
- Earlier prodrug patents from the same assignee group that establish core conversion chemistry
- Later optimization patents around salts, polymorphs, particle engineering, and dissolution testing
- Drug product patents that claim oral solid dosage forms and stability testing methods
Even without reproducing the complete citation graph here, the landscape’s practical shape is consistent:
- Core chemical families at earlier filing dates
- Product-improvement families that extend into later years
- Competing prodrug approaches that attempt to avoid the specific promoiety definitions while retaining the conversion goal
How long does protection typically last in this class, and what does that mean for today?
WO publications disclose an invention date but enforceability depends on national phase filings and the maintenance of rights. Typical patent term mechanics in major jurisdictions run to about 20 years from the earliest priority date, subject to:
- any patent term adjustments
- regulatory exclusivity overlap (if applicable)
- terminal disclaimers in the US
- validity challenges and claim narrowing by prosecution
For a 2004 publication, the earliest priority is usually late-1990s to early-2000s, meaning many original rights likely expired or were narrowed by now, while later product-improvement patents can extend market coverage depending on their priority dates.
Key claim-scope takeaways for investors and R&D teams
What is the highest-value scope to extract from WO2004035020?
For this patent type, the highest-value scope extraction is:
- Independent compound/prodrug claim definition: whether it is generic or specific
- Promoiety and conversion mechanism boundaries: what chemical classes are included/excluded by the claim language
- Formulation claim constraints: excipients and performance parameters (if claimed)
- Medical-use breadth: the condition/indication categories and whether they are defined broadly or narrowly
Where do design-arounds usually work best?
- Chemical definition changes: swapping the promoiety class or the conversion logic outside the claimed structural definitions
- Formulation parameter changes: changing excipient selection and/or dissolution-linked constraints so the product falls outside literal formulation claims
- Use/label navigation: limiting marketing to indications not covered by the claimed medical-use language (where legally available and commercially viable)
Key Takeaways
- WO2004035020 sits in a 2004-era prodrug/formulation patent pattern where claim scope is usually driven by (1) prodrug chemical definitions, (2) formulation composition parameters, and (3) medical-use language.
- The market-exposure risk profile is mostly determined by whether independent claims define broad prodrug classes or tight prodrug structures, and whether formulation claims impose specific excipient or performance conditions.
- For FTO and investment decisions, prioritizing extraction of the independent prodrug/compound claim and any independent formulation and use claims produces the fastest, highest-signal assessment of enforceability and design-around pathways.
FAQs
1) Is WO2004035020 mainly about a compound or a product (formulation)?
It is primarily structured like most 2004 prodrug PCT filings: compound/prodrug claims set chemical scope, while formulation and use claims extend enforcement to product and indication.
2) What is the biggest lever for reducing FTO risk?
Changing the product so it falls outside the independent chemical definition boundaries and, secondarily, outside independent formulation/use claim language.
3) Do dependent claims matter if independent claims are broad?
Yes. Dependent claims define narrower fences that can still be asserted if the competitor product maps to those subsets, especially if prosecution narrowed the independent claim scope.
4) How do improvements around salts, polymorphs, and dissolution affect this landscape?
They often create follow-on protection that can outlast the core compound patents, especially if the later family members have later priority dates tied to formulation performance.
5) How is enforcement typically pursued for prodrug patents?
Through product sales when formulation claims apply, and through labeling/indication strategies when medical-use claims align with the marketed indication.
References
[1] World Intellectual Property Organization (WIPO). WO2004035020. WIPO publication (2004).
